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Annexins are calcium-binding proteins that interact with cellular membranes due to their ability to bind phos-
pholipids. The structural and functional peculiarities of these proteins have been described. Being cytosolic 
proteins, annexins also possess extracellular activities. However, there are some controversial opinions con-
cerning the functional role of extracellular annexins in the human hemostasis system. We have made an at-
tempt to summarize the latest data and consider some ideas of possible annexin application in medical practice.
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Annexins are considered as a family of calcium-de-
pendent phospholipid-binding proteins. The struc-
ture of these proteins has some common features [1] 
(Fig.1). As a rule, annexins possess a variable ami-
no-terminal domain and a carboxyl core domain. 
The last one is typically divided into four homolo-
gous domains (each of them is about 70 amino acid 
residues) and each of these domains consists of five 
α-helices. The amino-terminal domain contains sites 
for posttranslational modification and protein-pro-
tein interaction. It has to be noted that this domain 
provides the stability of the whole protein struc-
ture [2]. Posttranslational modifications in this re-
gion such as phosphorylation, acetylation or proteo-
lysis make influence on the structure of key regions 
of the protein core even though they take place at the 
opposite side of the annexin molecule. The carboxyl 
core domain houses one or several calcium-binding 
motives (KGXGT-38 residues-D/E). Apart from the 
calcium-binding sites, in this domain there are also 
the sites for binding to heparin, F-actin and phospho-
lipids (such as phosphatidyl serine and phosphati-
dylethanolamine). The annexins have been shown to 
take part in many processes: exocytosis, endocyto-
sis, inhibition of blood coagulation, regulation of ion 
transport across membranes, membrane reorganiza-
tion, vascular trafficking and redox regulation [3, 4]. 
In this review we mostly paid attention to those 
members of annexin family that can be found in the 
human hemostasis system. Normally annexins are 
not secreted from the living cells, and the appear-
ance of these proteins in bloodstream can be con-
side red as a result of the cell degradation or apopto-
sis [5]. It is known that annexins lack the signal se-
quences that could direct them into the classical se-
cretory pathway. However, for annexins A1, A2 and 
A5 the extracellular activity has been shown. Thus, 
annexin A5 is considered as an anticoagulant pro-
tein, annexin A2 as an endothelial receptor for plas-
minogen and tissue plasminogen activator (tPA), and 
annexin A1 as an anti-inflammatory agent [6].
Annexin A1 and its role in inflammation
Annexin A1 has the longest history of reported ex-
tracellular activity. It was found in human serum at 
some pathological states such as myocardial infarc-
tion and experimental colitis [7,8]. The role of an-
nexin A1 in inflammation is related with glucocorti-
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coids as the main mechanism of glucocorticoids’ 
anti-inflammatory effects is an increase of the syn-
thesis and function of annexin A1 [9]. Glucocorticoids 
bind to the cytosolic glucocorticoid receptor, a type 
of nuclear receptor that is activated by the ligand 
binding. After the hormone binds to the receptor, the 
newly formed complex translocates itself into the 
cell nucleus, where it binds to the glucocorticoid re-
sponse elements in the promoter region of annexin 
A1 gene resulting in stimulation of the gene expres-
sion [10]. Annexin A1 inhibits phospholipase A2. 
This is a calcium-dependent enzyme acting on phos-
pholipids of membranes that releases arachidonic 
acid from the second carbon group of glycerol. 
Arachidonic acid is a precursor of prostaglandins 
and leucotriens playing the key role in the inflamma-
tory reactions. On the other hand, annexin A1 may 
be considered as a regulator of leukocyte migration 
[11, 12]. As it is known, there are specific A1 recep-
tors on the human neutrophils and monocytes [13]. 
They belong to the formyl peptide receptor (FRP) 
family of chemoattractant receptors. FRPs are the 
G-protein-coupled receptors, and they were identi-
fied by their ability to bind N-formyl peptides con-
taining an N-terminal N-formylmethionine produced 
by the degradation of either bacterial or host cells 
(they can be released by the mitochondria). The for-
myl peptide receptor (FPR) signaling pathways in-
clude the following steps: G-protein dependent acti-
vation of phospholipase C, activation of the regula-
tory small GTP-ase, and activation of CD38, ectoen-
zyme of the membrane surface. The final result of 
the process is an increase in the cytoplasmic Ca2+ 
level. The sustained increase of calcium is required 
for directed migration of the cells [14]. The sequenc-
es located in the unique N-terminal domain of an-
nexin A1 specifically interact with the formyl pep-
tide receptor on neutrophils, thereby eliciting the 
receptor-mediated intracellular responses leading to 
the inhibition of transendothelial migration.
Annexin A2 as a receptor on leukocytes and 
endothelial cells
Annexin A2 found on the surface of endothelial cells 
and leukocytes can function as a receptor for plas-
minogen and tPA acting as a positive modulator of 
the fibrinolytic cascade. The increased expression of 
annexin A2 on the surface of leukemic cells derived 
from the acute promyelocytic leukemia patients cor-
relates with the clinical manifestation of blee-
ding [15].
Endothelial cells are thought to play a key role in 
the intravascular plasmin generation, as they syn-
thetize and secrete plasminogen activators (tPA and 
uPA) and their inhibitors (PAI-1) [16]. It is remark-
able that on endothelial cells, annexin A2 is consti-
tutively translocated to the cell surface within 
16 hours of its biosynthesis where it may consist 
5 % of the cellular protein pool [17]. Exogenous I125 
–labeled annexin A2 bound to endothelial cell sur-
face with high affinity (Kd 49nM) in a calcium-de-
pendent manner. This binding may be blocked by 
Fig. 1. Schematic representation of an-
nexin structure: 
 ‒ calcium binding motive, 
 ‒ binding protein, 
 ‒ phosphate group. 
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peptides mimicking the classical “annexin repeat” 
(KGXGT) [16]. 
Annexin A2 is thought to be a major membrane re-
ceptor of tPA on endothelium [18]. It has been shown 
that tPA, plasminogen and plasmin bind to annexin 
A2 through protein p11 with different affinity (Kd 
0.68 µM, 0.11 µM and 75 nM respectively) [19]. 
There is a tight hydrophobic interaction between p11 
and annexin A2. Complex p11-annexin A2 binds tPA, 
plasmin and plasminogen due to the C-terminal lysine 
residue of the p11 molecule [1]. The formed complex 
can provide generation of the extracellular plasmin 
(plasminogen is converted into plasmin by cleaving 
peptide bond between Arg 561 and Val 562 by tPA) 
[20]. However, the proposed profibrinolytic function 
of annexin A2 is somewhat controversial, as there are 
the data, that annexin A2 in complex with p11 can 
also inhibit the plasmin activity and fibrinolysis [21].
Recently, it has been demonstrated that the tPA - 
annexin A2 interaction may play a significant role 
during inflammation process (Fig.2).
Under the stimulation of tPA, annexin A2 aggre-
gates with β-2 integrin CD 11b, leading to the activa-
tion of integrin-linked kinase (ILK) pathway [22]. 
Thus, annexin A2 can transduce tPA signaling 
through its interaction with integrins. Annexin A2 
mediates tPA-induced NF-kB activation in macro-
phages. In physiological status, the members of NF-
kB family (p50, p52, p65 and other) are retained in 
the cytoplasm by the specific inhibitor IkB. Upon 
activation, IkB becomes phosphorylated, which 
leads to its degradation and the release of NF-kB di-
mers into nuclei. It results in the subsequent DNA 
binding and transcription of the target proinflamma-
tory genes. Blocking any step of this cascade (e.g. 
using annexin A2 antibodies) eliminates the tPA-in-
duced NF-kB activation.
Annexin A5 as an anticoagulant factor and 
apoptosis marker
Annexin A5 was originally isolated from the human 
umbilical cord artery by virtue of its anticoagulant ac-
Fig. 2. tPA-induced NF kB activation in 
human macrophages: ann A2 – annexin 
A2, Plg – plasminogen, Pm – plasmin, 
tPA – tissue plasminogen activator, ILK – 
integrin linked kinase, Pi – phosphate 
group.
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tivity [23]. As it was mentioned above, all calcium-
binding annexins are thought to be natural anticoagu-
lants. It is known that the phosphatidyl serine (PS) 
exposure on the outer membrane is the characteristic 
of the activated platelets or endothelial cells [24]. PS 
facilitates the assembly and activation of the tenase 
and prothrombinase complexes [25]. The annexin A5 
binding to PS results in formation of an anticoagulant 
shield on the cell membrane [5].This shield is of great 
importance for placental cells as annexin A5 binds to 
the apical surface of placental syncytiotrophoblasts 
providing maintenance of normal blood flow through 
the placenta. The disruption of the shield leads to the 
development of antiphospholipid syndrome. As a re-
sult the apical surface of placenta becomes thrombo-
genic and patients with antiphospholipid syndrome 
suffer from recurrent pregnancy losses [26]. It has 
also been shown that extracellular as well as cytosolic 
annexin A5 binds to the disrupted site of injured plas-
ma membrane as early as a few seconds after mem-
brane wounding and promotes membrane resealing 
[27]. All these data raise the question of a role of an-
nexin A5 in the protection and repair of membrane 
injuries in trophoblasts.
On the other hand, annexin A5 is the main annexin 
of human platelets [28]. Annexin A5 binds to platelets 
with high affinity (Kd 7nM) [29]. It was found that 
each platelet has approximately 5,000 sites to bind an-
nexin A5. After thrombin stimulation, the amount of 
annexin-binding sites per platelet can reach 200,000. 
The treatment with phospholipase C or adding phos-
pholipase preparations to the platelet mixture led to 
inhibition of annexin A5 binding [30]. Annexin A5 is 
also exposed on the apoptotic platelets [31]. During 
platelet apoptosis, the PS exposure occurs via the cas-
pase and calpain activation, when platelets undergo a 
cellular death pathway leading to their clearance from 
the circulation by scavenger cells [32]. These events 
could be also induced in vitro by thrombin. It is re-
markable, that the aging and stored platelets were also 
positive for PS [33]. However, it is necessary to carry 
out the analysis of other biomarkers to distinguish the 
platelet activation and apoptosis-mediated changes 
from each other [34]. 
So, annexin A5 can serve as a marker of activated 
or apoptotic platelets and its determination in blood 
and on the surface of blood cells or endothelium can 
be very important for the diagnosis and treatment of 
hemostasis disorders [35].
Annexin A5 effect on plasminogen binding
In the presence of apoptotic factors, plasminogen 
considerably increases phosphatidyl serine exposure. 
This effect was shown for monocytes and neutro-
phils. The increased exposure of phosphatidyl serine 
is associated with the growing plasminogen binding 
to the cell surface [36]. This effect is explained by the 
histone H2B exposure on the surface of apoptotic 
monocytes. Histone H2B has different binding sites 
for phosphatidyl serine and plasminogen and can 
provide the efficient binding of both components 
with the cell surface. Annexin A5 competes with his-
tone H2B for phosphatidyl serine binding and as a 
result plasminogen binding to cells is inhibited.
On the other hand, the platelet activation with 
thrombin led to an increased exposure of phosphati-
dyl serine in case of platelets and, as a result, eleva-
ted plasminogen binding was observed on the plate-
let surface [37]. The phosphatidyl serine exposure in 
these experiments was detected using annexin A5. It 
was found a special place on the platelet surface, so-
called protruding “cap”, where plasminogen [37], 
thrombospondin and fibrinogen/fibrin were coloca-
lized [38]. As this “cap” was also the localization 
place for factor XIIIa [39], it was suggested that fib-
rin plays a special role in amplifying the plasmino-
gen binding to annexin A5 bound platelets [37].
 However, we could also observe the plasminogen 
effect on the annexin A5 binding in case of activated 
platelets [40]. In our experiments the exogenous 
plasminogen preincubated with washed human 
platelets leads to the increased exposure of annexin 
A5 on the platelet surface after the thrombin stimula-
tion. As there are no data about the formation of an-
nexin A5-plasminogen complex, and histon H2b is 
not exposed on the platelet surface, the mechanism 
of the observed effect may be clarified only after se-
ries of further investigations. 
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Future perspective
Although numerous studies clearly indicate that ex-
tracellular annexins play an important role in the 
functioning of human organisms, there are still many 
gaps in our understanding of the molecular mecha-
nisms underlying their action. The structural pecu-
liarities of annexins may be very important in this 
case. As it was shown some annexins (A2 and A5) 
interact with carbohydrates, in particular glycosami-
noglycans. These interactions are likely to come into 
play only for extracellular annexins but functional 
significance of this binding remains to be proven 
[41,42]. On the other hand, there are some proposals 
for practical application of annexins in medical prac-
tice. It has been reported about diannexin, an annex-
in A5 homodimer that binds phosphatidyl serine 
with high affinity (0.6 nM) [43]. This new prepara-
tion may find practical application in medicine due 
to its ability to reduce the surface area coverage by 
platelets perfused with human blood and to inhibit in 
vivo the thrombus formation and fibrin deposition in 
the rat and rabbit models of arterial and venous 
thrombosis. 
There are numerous reports about the agents con-
structed on the annexin base as apoptotic markers 
[44-46]. Elevated annexin V levels have been found 
in acute and chronic renal conditions [47]; in pa-
tients with heart failure a high circulating annexin 
V level is likely to reflect peripheral organ damage 
[48]. Some annexins can be predicted as therapeutic 
agents. So, annexin V can be used in treatment of the 
patients with sickle cell disease [49]. There are some 
interesting reports concerning using annexin V as a 
potential marker in tumors [50,51] and as a thera-
peutic agent for the patients with diffuse large B-cell 
lymphoma [52].
However, future investigations are needed to clar-
ify the precise way of the annexin turnover in human 
organism.
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Позаклітинні анексини у системі гемостазу
Д. Д. Жерносєков, Я. М. Рока-Мойя, T. В. Гриненко
Аннесини – це кальцій-залежні протеїни, що взаємодіють з 
клітинними мембранами завдяки їх властивості зв’язувати 
фосфоліпіди. Структурно-функціональні особливості цих про-
теїнів надані в науковій літературі. Хоча анексини – цитозольні 
протеїни, для них притаманна позаклітинна активність. 
Існують суперечливі дані стосовно ролі позаклітинних анекси-
нів у системі гемостазу. Ми спробували систематизувати су-
часні наукові дані та виявити можливе застосування анексинів 
у медичній практиці.
К л юч ов і  с л ов а: анексини, гемостаз, плазміноген/плазмі-
нова система.
Внеклеточние аннексины в системе гемостаза
Д. Д. Жерносеков, Я. М. Рока-Мойя, T. В. Гриненко
Аннексины – это кальций-зависимые протеины, которые взаи-
модействуют с клеточными мембранами благодаря их способ-
ности связывать фосфолипиды. Структурно-функциональные 
особенности этих белков описаны в научной литературе. Хотя 
аннексины – цитозольные протеины, для них показана внекле-
точная активность. Существуют противоречивые мнения каса-
тельно функциональной роли внеклеточних аннексинов в си-
стеме гемостаза. Мы предприняли попытку систематизировать 
последние научные данные и рассмотреть возможное приме-
нение аннексинов в медицинской практике. 
К л юч е в ы е  с л ов а: аннексины, гемостаз, плазминоген/
плазминовая система.
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